ClinicalTrials.gg
CompletedNCT07154901Updated Jun 26, 2026

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

A Phase 1 interventional study of Opemalirsen (AZD2373) in Renal Impairment, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
11th of 29
35 · median 24
Started
2025
with 1 other
Phase 1
26 of 29
none open now
Registered
28th of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 11th largest by enrollment, is one of 2 that started in 2025, is one of 26 in phase 1, and was the 28th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

This study is being conducted to investigate the PK, safety, and tolerability of opemalirsen in participants with renal impairment, compared to participants with normal renal function.

Read the detailed description

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study, that will be conducted in 2 parts, to examine the PK, safety, and tolerability of opemalirsen in male and female participants with severe renal impairment to matched participants with normal renal function; and, if necessary, participants with mild and moderate renal impairment to matched participants with normal renal function.

Potential participants will be screened to assess their eligibility to enter the study within 28 days prior to first dose administration. Participants will be assigned to the following groups based on BSA-adjusted eGFR at screening using the creatinine-based CKD-EPI (2021) race-free estimation of eGFR:

  • Part 1:

    • Group 1: Participants with normal renal function (eGFR ≥ 90 mL/min; n = 8 to 20 participants)
    • Group 2: Participants with severe renal impairment not on dialysis (eGFR \< 30 mL/min; n = 8 to 10 participants)
  • Part 2 (Optional):

    • Group 3: Participants with moderate renal impairment (eGFR ≥ 30 mL/min to \< 60 mL/min; n = 8 to 10 participants)
    • Group 4: Participants with mild renal impairment (eGFR ≥ 60 mL/min to \< 90 mL/min; n = 8 to 10 participants)

If the data from Part 1 demonstrate that severe renal impairment does not alter PK of opemalirsen to an extent which would warrant dose adjustment, then Part 2 will not be pursued. If the PK data of the study support a dosage adjustment in patients with severe renal impairment, then participants will be enrolled Group 3 and/or Group 4 in Part 2. Additional participants may be enrolled in Group 1 (not exceeding n = 20) and dosed in parallel with Part 2, if required, to match participants in Groups 3 and/or 4.

Each matched participant with normal renal function (Group 1) enrolled in the study will be demographically matched by sex, age (± 10 years), and BMI (± 20%), data obtained at screening, to an enrolled participant with renal impairment. Participants with normal renal function cannot be matched to more than one participant with renal impairment within an impairment group; however, participants with normal renal function may be matched to

1 participant from more than 1 renal impairment group.

Eligible participants will be admitted to the study site on Day -1. On Day 1, participants will receive a single SC injection of opemalirsen. Participants will be confined to the study site until Day 3 and will return for follow-up visits 1, 2, 3, and 8 weeks post-dose.

Serial PK (venous) blood samples and urine samples will be collected up to 48 hours post-dose (Day 3) for the measurement of opemalirsen in plasma and urine. Additional blood samples will be collected the follow-up visits 1, 2, and 3 weeks post-dose for the measurement of opemalirsen in plasma. Adverse events and serious adverse events will be recorded and physical examinations, 12-lead electrocardiograms, vital sign measurements, and clinical laboratory tests will be performed to assess safety and tolerability.

03

Conditions studied

  • Renal Impairment

Keywords

  • Renal impairment
  • AZD2373
  • Pharmacokinetics
  • Severe
  • Mild
  • Moderate
  • Matched Healthy Controls
  • opemalirsen
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:

Age

  1. Participant must be 18 to 80 years of age, inclusive, at the time of signing the . Type of Participant and Disease Characteristics For all participants, BSA-adjusted will be determined by the local laboratory, calculated based on serum creatinine using the CKD-EPI equation (see Section 4.1).

    Healthy matched control participants only (Group 1):

  2. Participant must be medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead ECGs, as deemed by the investigator at screening and Day -1.
  3. Have an eGFR of ≥ 90 mL/min determined at screening.

Participants with renal impairment only (Group 2 and optional Groups 3 and 4):

4 Diagnosis of chronic kidney disease with stable renal function in the 3 months prior to dosing, as determined by the investigator, based on medical history or eGFR, and not requiring dialysis. 5 Participants with renal impairment, as follows, based on CKD-EPI equation (BSA-adjusted eGFR) at screening:

  1. Group 2: have severe renal impairment (eGFR \< 30 mL/min), not requiring dialysis.
  2. Group 3 (optional): have moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min)
  3. Group 4 (optional): have mild renal impairment (eGFR ≥ 60 to \< 90 mL/min) 6 Participants on angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blocker, diuretics, or on any other cardiorenal relevant treatment should be on a stable dose for at least 2 weeks prior to screening. Weight 7 Body weight of at least 50 kg and (BMI) within the range 18 to 40 kg/m2 (inclusive). Sex and /Barrier Requirements 8 Male and/or female, assigned at birth, inclusive of all gender identities. 9 Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

(a) Male participants must agree to the following contraception guidance for the duration of the study (from the time of study intervention administration) until 3 months after discharge: (i) Non-sterilised male participants should avoid fathering a child by either true abstinence or by using (together with their female partner/spouse) a highly effective contraception form of birth control in combination with a barrier method, starting from the time of study intervention administration until 3 months after discharge. Acceptable methods of preventing pregnancy include birth control pills, injections, implants, or patches, IUDs, tubal ligation/occlusion, and vasectomy. (ii) Male participants who have been sterilised are required to use one barrier method of contraception (condom) from the time of study intervention administration until after discharge. A barrier method is not necessary if the female partner is sterilised. (iii) Male participants should not donate sperm from the time of study intervention administration until 3 months after discharge. (b) Female participants: must not be pregnant and must have a negative pregnancy test at screening (all female participants) and check-in () and must not be lactating.

Women of Childbearing Potential (WOCBP): A woman is considered of childbearing potential if she is capable of conceiving. While this is typically the case following menarche and up until she becomes , adolescents can ovulate prior to first menarche, and women with irregular menses may also be fertile. Women Not of Childbearing Potential (WNOCBP): Females not of childbearing potential are defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are post-menopausal. Females will be considered post-menopausal if they have been amenorrhoeic for 12 months prior to the planned date of dose administration without an alternative medical cause. The following age-specific requirements apply:

  • Females \< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
  • Females ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment. (i) Female participants should be stable on the chosen method of contraception for a minimum of 3 months before entering the study. (ii) Female participants of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Females of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, throughout the study and until at least 3 months after discharge. Cessation of contraception after this point should be discussed with a responsible physician. Note: contraception is not required for female participants of non-childbearing potential.

    • Highly effective birth control methods include:

      • Non-hormonal • Total sexual abstinence provided it is the usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) • a vasectomised partner (confirmed absence of sperm in semen) • bilateral tubal occlusion

        • intrauterine device (copper)
      • Hormonal contraceptives associated with inhibition of ovulation levonorgestrel intrauterine system • medroxyprogesterone injections • combined Oral or transdermal contraceptives (ethinyl estradiol plus progestin) • intravaginal device (eg, EE and etonogestrel) The following are not acceptable methods of contraception: female condom, periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea.

Exclusion criteria

Exclusion Criteria:

  • Medical Conditions

All participants:

  1. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator, at screening or Day -1, or history of hypersensitivity to drugs with a similar chemical structure or class to opemalirsen.
  2. History of any major surgical procedure within 30 days prior to study intervention.
  3. Judgement by the investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or if they are considered unlikely to comply with study procedures, restrictions, and requirements.
  4. Liver disease (non-alcoholic and alcoholic steatohepatitis; drug-induced, viral, or hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease) including positive results for surface antigen, hepatitis B core antibody or virus antibody.
  5. History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding.
  6. > 470 ms in participants without bundle branch block and > 480 ms in participants with bundle branch block.
  7. Any of the following out of range laboratory values:

    1. or AST > 1.5 ×
    2. TBL > ULN (an isolated increase in TBL in participants with Gilbert syndrome is not a reason for exclusion)
    3. > 1.2, unless related to therapeutic anticoagulation
    4. APTT ≥ 1.3 × normal, unless related to therapeutic anticoagulation
    5. ≥ 10%
  8. Positive test for at screening.
  9. Known history of drug or alcohol abuse within 1 year of screening.

    Healthy matched control participants only (Group 1):

  10. Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal including bone fractures, endocrine including adrenal insufficiency, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may put the participant at risk because of participation in the study, influence the results of the study, or affect the participant's ability to participate in the study.
  11. Abnormal resting vital signs (after resting for 10 minutes) of supine BP > 150 mmHg or \< 90 mmHg systolic or > 95 mmHg or \< 50 mmHg diastolic or supine pulse rate ≥ 100 bpm or ≤ 45 bpm. Note: the blood pressure values will be based on the average of the 3 measurements.

    Participants with renal impairment only (Group 2 and optional Groups 3 and 4):

  12. Evidence of rapidly deteriorating renal function.
  13. Presence of unstable medical (eg, diabetes) or psychological conditions which, in the opinion of the investigator, would compromise the participant's safety or successful participation in this study.
  14. Renal transplant patients, that is, participants that have received a kidney transplant or participants waiting for organ transplant scheduled to occur during the study, and those with a history of acute kidney injury occurring within 3 months prior to screening.
  15. Abnormal resting vital signs (after resting for 10 minutes) of supine BP > 180 mmHg or \< 110 mmHg systolic or > 110 mmHg or \< 60 mmHg diastolic or supine pulse rate ≥ 100 bpm or ≤ 40 bpm. Note: the blood pressure values will be based on the average of the 3 measurements.

    Prior/Concomitant Therapy

    Healthy matched control participants only (Group 1):

  16. Use of any prescription or non-prescription drugs (including vitamins, recreational drugs, and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before study intervention, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.

    Participants with renal impairment only (Group 2 and optional Groups 3 and 4):

  17. Use of concurrent medication, which affect such as cephalosporin antibiotics, ascorbic acid, trimethoprim, cimetidine, quinine within 7 days prior to Day -1.

    Prior/Concurrent Clinical Study Experience

    All participants:

  18. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days of study intervention in this study or, if known, 5 half-lives from last dose in the previous study to study intervention in this study, whichever is longest.
  19. Previous enrolment in the present study. Note: participants consented and screened, but not receiving study intervention in this study or a previous Phase I study, are not excluded. Other Exclusions

    All participants:

  20. Positive screen for drugs of abuse (unless participant has renal impairment and positive screen is due to medication[s] prescribed by physician) and/or alcohol test at screening or Day -1; a positive result for tetrahydrocannabinol and/or cannabinoids is not considered exclusionary.
  21. Receipt of blood products within 2 months prior to Day -1, plasma or donation within 1 month prior to Day -1, or any blood donation/blood loss > 500 mL within

3 months prior to Day -1. 22 Involvement of any AstraZeneca or clinical unit employee or their close relatives.

23 Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order. 24 Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Group 1

    Healthy participants will receive a single subcutaneous injection of AZD2373.

    Drug: Opemalirsen (AZD2373)

  • Experimental
    Group 2

    Severe renal impairment participants will receive a single subcutaneous injection of AZD2373.

    Drug: Opemalirsen (AZD2373)

  • Experimental
    Group 3

    Moderate renal impairment participants will receive a single subcutaneous injection of AZD2373

    Drug: Opemalirsen (AZD2373)

  • Experimental
    Group 4

    Mild renal impairment participants will receive a single subcutaneous injection of AZD2373

    Drug: Opemalirsen (AZD2373)

Interventions

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under the concentration-time curve from zero to infinity

    Time frame: Pre-dose to 3 weeks post dose

  2. AUClast

    Area under the concentration-time curve from zero to the last measurable concentration

    Time frame: Pre-dose to 3 weeks post-dose

  3. Cmax

    Maximum observed plasma concentration

    Time frame: Pre-dose to 3 weeks post-dose

Secondary outcomes

  1. Tmax

    Time to reach maximum observed plasma concentration

    Time frame: Pre-dose to 3 weeks post-dose

  2. t1/2λz

    Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve

    Time frame: Pre-dose to 3 weeks post-dose

  3. CL/F

    Apparent total body clearance of drug from plasma after extravascular administration

    Time frame: Pre-dose to 3 weeks post-dose

  4. Vz/F

    Apparent volume of distribution during the terminal phase after extravascular administration

    Time frame: Pre-dose to 3 weeks post-dose

  5. Fu

    Fraction unbound

    Time frame: Pre-dose to 3 weeks post-dose

  6. CLr

    Renal clearance of the drug from plasma

    Time frame: Pre-dose to 3 weeks post-dose

  7. Ae

    Cumulative amount of unchanged drug excreted into the urine

    Time frame: Pre-dose to 3 weeks post-dose

  8. fe

    Fraction of the drug excreted into the urine

    Time frame: Pre-dose to 3 weeks post-dose

Other outcomes

  1. Number of Participants with Abnormal AEs and SAEs

    Adverse Events and Serious Adverse Events

    Time frame: Screening to Day 57

07

Study locations

2 sites
  • Research Site
    Miami, Florida 33172, United States
  • Research Site
    Orlando, Florida 32808, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jun 2026, 9 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Sep 4, 2025
StartActual
Aug 18, 2025
Primary completionActual
Jun 15, 2026
CompletionActual
Jun 15, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154901
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Aug 18, 2025
Primary completion
Jun 15, 2026
Completion
Jun 15, 2026
Last update
Jun 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opemalirsen

Start the discussion